Lineage Cell Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Lineage Cell Therapeutics, Inc. (LCTX) reported Earnings Per Share, Basic and Diluted of -$0.26 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-03-10
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2016-12-31 was -$0.05.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2016-09-30 was $0.30.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2016-06-30 was $0.26.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2016-03-31 was -$0.19.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.26.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.14.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$0.08.
- Lineage Cell Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$0.36.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$0.26 10-K · filed 2022-03-10 | |||
| 2020-12-31 | -$0.14 10-K · filed 2022-03-10 | |||
| 2019-12-31 | -$0.08 10-K · filed 2021-03-11 | |||
| 2018-12-31 | -$0.36 10-K · filed 2020-03-12 | |||
| 2017-12-31 | -$0.17 10-K · filed 2019-03-14 | |||
| 2016-12-31 | -$0.05 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $0.30 10-K · filed 2017-03-16 | |||
| 2016-06-30 | $0.26 10-K · filed 2017-03-16 | |||
| 2016-03-31 | -$0.19 10-K · filed 2017-03-16 | |||
| 2015-12-31 | -$0.16 10-K · filed 2017-03-16 | -$0.34 derived: net income ÷ weighted average shares · filed 2018-03-15 | -$0.46 derived: net income ÷ weighted average shares · filed 2018-03-15 | -$0.59 10-K · filed 2016-03-15 |
| 2015-09-30 | -$0.18 10-K · filed 2017-03-16 | -$0.30 derived: net income ÷ weighted average shares · filed 2016-11-04 | -$0.43 10-Q · filed 2015-11-09 | -$0.57 derived: net income ÷ weighted average shares · filed 2017-03-16 |
| 2015-06-30 | -$0.12 10-K · filed 2017-03-16 | -$0.25 10-Q · filed 2015-08-10 | -$0.39 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$0.51 derived: net income ÷ weighted average shares · filed 2017-03-16 |
| 2015-03-31 | -$0.13 10-K · filed 2017-03-16 | -$0.27 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$0.39 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$0.54 derived: net income ÷ weighted average shares · filed 2017-03-16 |
| 2014-12-31 | -$0.14 10-K · filed 2016-03-15 | -$0.26 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$0.41 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$0.55 10-K · filed 2016-03-15 |
| 2014-09-30 | -$0.12 10-K · filed 2016-03-15 | -$0.28 derived: net income ÷ weighted average shares · filed 2015-11-09 | -$0.41 10-Q · filed 2015-11-09 | -$0.75 derived: net income ÷ weighted average shares · filed 2016-03-15 |
| 2014-06-30 | -$0.16 10-K · filed 2016-03-15 | -$0.29 10-Q · filed 2015-08-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2016-03-15 | -$0.80 derived: net income ÷ weighted average shares · filed 2016-03-15 |
| 2014-03-31 | -$0.14 10-K · filed 2016-03-15 | -$0.48 derived: net income ÷ weighted average shares · filed 2016-03-15 | -$0.65 derived: net income ÷ weighted average shares · filed 2016-03-15 | -$0.79 derived: net income ÷ weighted average shares · filed 2016-03-15 |
| 2013-12-31 | -$0.35 10-K · filed 2015-03-11 | -$0.51 derived: net income ÷ weighted average shares · filed 2016-03-15 | -$0.65 derived: net income ÷ weighted average shares · filed 2016-03-15 | -$0.81 10-K · filed 2016-03-15 |
| 2013-09-30 | -$0.16 10-K · filed 2015-03-11 | -$0.30 derived: net income ÷ weighted average shares · filed 2014-11-07 | -$0.45 10-Q · filed 2014-11-07 | |
| 2013-06-30 | -$0.14 10-K · filed 2015-03-11 | -$0.29 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | -$0.15 10-K · filed 2015-03-11 | |||
| 2012-12-31 | -$0.12 10-K · filed 2014-03-17 | -$0.44 10-K · filed 2015-03-11 | ||
| 2012-09-30 | -$0.10 10-K · filed 2014-03-17 | -$0.31 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | -$0.11 10-K · filed 2014-03-17 | -$0.21 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | -$0.10 10-K · filed 2014-03-17 | |||
| 2011-12-31 | -$0.10 10-K · filed 2013-03-18 | -$0.35 10-K · filed 2014-03-17 | ||
| 2011-09-30 | -$0.08 10-K · filed 2013-03-18 | -$0.23 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | -$0.09 10-K · filed 2013-03-18 | -$0.16 10-Q · filed 2012-08-09 | ||
| 2011-03-31 | -$0.07 10-K · filed 2013-03-18 | |||
| 2010-12-31 | -$0.28 10-K · filed 2013-03-18 | |||
| 2010-09-30 | -$0.11 10-Q · filed 2011-11-08 | -$0.22 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | -$0.06 10-Q · filed 2011-08-09 | -$0.10 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | -$0.18 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |